SAM
KYMR icon

Smartleaf Asset Management’s Kymera Therapeutics KYMR Stock Holding History

Smartleaf Asset Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.3K Buy
608
+73
+14% +$5.78K ﹤0.01% 1468
2025
Q4 		$41.8K Buy
535
+424
+382% +$28.6K ﹤0.01% 1641
2025
Q3 		$6.49K Buy
111
+55
+98% +$2.48K ﹤0.01% 2287
2025
Q2 		$2.47K Sell
56
-115
-67% -$3.96K ﹤0.01% 2271
2025
Q1 		$5.07K Buy
171
+40
+31% +$1.46K ﹤0.01% 2184
2024
Q4 		$5.15K Sell
131
-32
-20% -$1.45K ﹤0.01% 2238
2024
Q3 		$7.94K Sell
163
-41
-20% -$1.81K ﹤0.01% 1895
2024
Q2 		$6.16K Buy
204
+181
+787% +$6.27K ﹤0.01% 1694
2024
Q1 		$923 Buy
+23
New +$823 ﹤0.01% 1637

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Smartleaf Asset Management's KYMR Position: Q1 2026 in Review

Smartleaf Asset Management increased its Kymera Therapeutics (KYMR) stake by 14% in Q1 2026, buying an estimated $5.78K and bringing the position to 608 shares worth $48.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

Smartleaf Asset Management first reported a position in KYMR in Q1 2024 and has held it in 9 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Smartleaf Asset Management held 608 shares of Kymera Therapeutics worth $48.3K as of Q1 2026.
  • Smartleaf Asset Management bought 73 Kymera Therapeutics shares in Q1 2026, an estimated $5.78K.
  • Kymera Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #1468 holding.
  • Smartleaf Asset Management first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.